WIRE — JPMorgan sees Nifty 50 at 30,000 in its bull case, upgrades pharma to Neutral and expects double-digit India earnings growth despite margin pressure.
"We aggregate wires to encourage regional discovery, sending readers directly back to the original source to explore full coverage."
This is a normalized overview of the breaking feed event. The complete, official release detailing all points, background context, and statements remains hosted by the original publisher.